Economics of Innovation

News
March 2018

Minimal Access Surgery – Why Don’t We Do More?

News
March 2018

Our Contributions to the Economics of Personalised Medicine

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Economics of Innovation

2017 OHE Annual Report to the Charity Commission

The Impact of New Medicines in the NHS: 70 Years of Innovation

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Establishing a Reasonable Price for an Orphan Drug

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

00
07
08
09
10
11
12
13
14
15
00

Latest Research & Publications

What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment

Evaluating the Cost-effectiveness of Health System Strengthening: A Platforms Perspective

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

2018 OHE Annual Report to the Charity Commission

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Data Governance Arrangements for Real-World Evidence in Japan

Unrelieved Pain in Palliative Care in England

All Publications

Filter results by

Filter results by

Minimal Access Surgery – Why Don’t We Do More?

Our Contributions to the Economics of Personalised Medicine

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

2017 OHE Annual Report to the Charity Commission

The Impact of New Medicines in the NHS: 70 Years of Innovation

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Establishing a Reasonable Price for an Orphan Drug

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

Share on Mastodon